Table 2.
Univariate and multivariate Cox analysis of OS in training set
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Age | 536 | 1.039 (1.021–1.058) | < 0.001 | 1.054 (1.026–1.083) | < 0.001 | |
| T stage | 534 | |||||
| T1 | 139 | Reference | ||||
| T2 | 316 | 1.168 (0.674–2.025) | 0.580 | |||
| T3&4 | 79 | 1.119 (0.539–2.324) | 0.762 | |||
| N stage | 526 | |||||
| N0 | 262 | Reference | ||||
| N1 | 170 | 1.556 (0.910–2.663) | 0.106 | |||
| N2 | 62 | 1.407 (0.606–3.265) | 0.427 | |||
| N3 | 32 | 2.637 (1.004–6.924) | 0.049 | |||
| M stage | 451 | |||||
| M0 | 442 | Reference | ||||
| M1 | 9 | 1.455 (0.567–3.733) | 0.435 | |||
| ER status | 506 | |||||
| Negative | 110 | Reference | ||||
| Positive | 396 | 1.316 (0.681–2.543) | 0.413 | |||
| PR status | 505 | |||||
| Negative | 162 | Reference | ||||
| Positive | 343 | 1.030 (0.601–1.766) | 0.914 | |||
| HER2 status | 338 | |||||
| Negative | 267 | Reference | ||||
| Positive | 71 | 1.912 (0.912–4.011) | 0.086 | |||
| Menopause status | 459 | |||||
| Pre | 117 | Reference | Reference | |||
| Post | 342 | 2.605 (1.167–5.811) | 0.019 | 0.737 (0.256–2.123) | 0.571 | |
| Radiotherapy | 91 | |||||
| YES | 42 | Reference | ||||
| NO | 49 | 1.274 (0.283–5.745) | 0.753 | |||
OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; 95% CI, 95% confidence interval